VIFOR-PHARMA
26.5.2019 09:02:08 CEST | Business Wire | Press release
Nanopharmaceutics promises ground-breaking innovation in the development of medicines:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005014/en/
- The Vifor Pharma Group is endowing two professorships for Nanopharmaceutical and Regulatory Science at the University of Basel
- The commitment by Vifor Pharma and the University of Basel is aimed at ensuring Switzerland has the specialist knowledge and equipment needed to compete globally in this important emerging area of life sciences
- With this decision, Vifor Pharma is demonstrating its commitment to Switzerland as a world-leading location for pharmaceutical research and development
Nanomedicines are playing an increasingly important role in the development of innovative new medications. These drugs are able to overcome specific cellular barriers in the human body with a view to targeting their effect even more precisely. Nanopharmacy therefore promises to help advance medical science and bring significant benefit to patients.
At present, however, researchers are only just beginning to acquire the in-depth scientific insights needed for a fundamental understanding of the development of nanomedicines, their applications and especially the regulatory requirements for their approval across Europe and worldwide. Likewise, there is a lack of experts with the necessary specialist knowledge – and these experts are urgently needed in industry, at regulatory authorities and in medical practice, including in Switzerland. As with other areas of cutting-edge research, this will take the form of a global race: those able to present findings as quickly as possible will be able to assert themselves as a centre of excellence in nanopharmaceutics.
Spread over 10 years, the commitment of CHF 10 million by the Vifor Pharma Group is intended to establish the field of nanopharmacy research at the University of Basel and to support the training of corresponding experts. The newly-created professorships in Nanopharmaceutical and Regulatory Science will be based at the Department of Pharmaceutical Sciences. There are also plans to establish and develop an internationally renowned Excellence Platform for the development, authorisation and application of nanopharmaceuticals, as well as the training of experts in the field.
Vifor Pharma views its contribution as start-up funding for this Excellence Platform, which is supported and jointly endorsed by stakeholders from academia, industry and public authorities. The aim is for the platform to both focus on research and teaching, and also to seek out international partnerships, organise conferences and incorporate additional sponsors with a view to becoming a leading international centre for nanopharmacy. “In order to make rapid progress in nanopharmaceutics, we’re reliant on clear and scientifically sound parameters for authorisation and patient safety,” says Etienne Jornod, Executive Chairman of the Board of Directors at Vifor Pharma. “The field of nanopharmacy is growing quickly, and it’s important to secure a leading position in this innovative area of medicine with the help of qualified experts. That’s why we want to help ensure that Switzerland establishes a strong research foundation in this emerging area of pharmaceutical development.”
For the University of Basel, this collaboration marks an important step in the further development of its life sciences focal area. “We’re proud to be able to develop this promising field of research in collaboration with a major industrial partner,” says Professor Andrea Schenker-Wicki, President of the University of Basel. “The crucial thing here is that we’re not only developing the scientific foundations, but also training the experts who will take this knowledge with them into industry and public authorities.” It is, she says, a key step for Basel and Switzerland in terms of their ability to compete on the international stage.
Vifor Pharma Group
is a global pharmaceuticals company
headquartered in Switzerland. It aims to become the global leader in
iron deficiency, nephrology and cardio-renal therapies. The company is
the partner of choice for pharmaceuticals and innovative patient-focused
solutions. The Vifor Pharma Group strives to help patients around the
world with severe and chronic diseases lead better, healthier lives. The
company develops, manufactures and markets pharmaceutical products for
precision patient care. The Vifor Pharma Group holds a leading position
in all its core business activities and consists of the following
companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a
joint company with Fresenius Medical Care); Relypsa; and OM Pharma. The
Vifor Pharma Group is listed on the Swiss Stock Exchange (SIX Swiss
Exchange, VIFN, ISIN: CH0364749348).
For more information, please
visit www.viforpharma.com
.
In
Switzerland Vifor Pharma has four production and research & development
sites where the vast majority of medications are produced. Together with
company headquarters, these sites employ over 1,300 people in
Switzerland. The affiliate Vifor Pharma Switzerland is operating out of
Villars-sur-Glâne in the French speaking part of the country.
The University of Basel
has an international reputation of
outstanding achievements in research and teaching. Founded in 1460, the
University of Basel is the oldest university in Switzerland and has a
history of success going back over 550 years.
As a comprehensive
university offering a wide range of high-quality educational
opportunities, the University of Basel attracts students from
Switzerland and the entire world, offering them outstanding studying
conditions as they work towards their bachelor’s, master’s or PhD
degrees. Today, the University of Basel has around 13,000 students from
over a hundred nations, including 2,800 PhD students. The University of
Basel has seven faculties covering a wide spectrum of academic
disciplines. At the same time, the university has positioned itself
amidst the international competition in the form of five strategic focal
areas: Life Sciences, Visual Studies, Nanosciences, Sustainability and
Energy Research and European and Global Studies. In international
rankings, the University of Basel is regularly placed among the 100 top
universities in the world thanks to its research achievements.
The
University of Basel has deep roots in the economically powerful and
culturally rich Basel region. The university also works closely with
domestic and international partners to make relevant contributions to
the advancement of the sciences and society. This also means that the
University of Basel pays particular attention to aspects of
sustainability, equal opportunity and knowledge transfer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190526005014/en/
Contact:
Media Relations Vifor Pharma Heide Hauer Head of Corporate Communications +41 58 851 80 87 media@viforpharma.com
Media Relations University of Basel Matthias Geering Leiter Public Affairs, Kommunikation & Marketing +41 61 207 35 75 / +41 79 269 70 71 matthias.geering@unibas.ch
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICR Appoints Sukanti Ghosh as Partner, International Strategy & Markets18.2.2026 13:00:00 CET | Press release
Global Strategic Communications leader to drive ICR's expansion across Europe, Middle East, South Asia, and Africa ICR, a leading strategic communications and advisory firm, today announced the appointment of Sukanti Ghosh as Partner, International Strategy & Markets, effective February 2, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218511412/en/ Sukanti Ghosh headshot Based in London, Mr. Ghosh brings more than three decades of experience in global corporate affairs, financial communications, strategy, and issues management to ICR as the firm continues to grow its international footprint in Europe and across the Middle East, South Asia, and Africa. Mr. Ghosh joins ICR from the Vedanta Group, a $20bn diversified mining, energy and technology conglomerates, where he served as President of Global Policy & Communications and led financial communications for the group, globally. During his tenure, he also played a ce
Macrobond Recognized in G2’s 2026 Best Software Awards for Financial Services and New Software18.2.2026 13:00:00 CET | Press release
Macrobond, the global platform for macroeconomic and financial data, today announced it has been named to G2’s 2026 Best Software Awards, earning recognition in the Best Financial Services Software Products and Best New Software Products categories. As the world’s largest and most trusted software marketplace, G2 reaches more than 100 million buyers annually. Its annual Best Software Awards rank the world’s leading software companies and products based on authentic, timely reviews from real users. “As buyers increasingly shift to AI driven research to discover software solutions, being recommended in the answer moment must be earned with credible proof,” said Godard Abel, co founder and CEO at G2. “Our Best Software Awards are grounded in trusted data from authentic customer reviews. They not only give buyers an objective, reliable guide to the products that help teams do their best work, but they are also the proof AI search platforms rely on when sourcing answers. Congratulations to
Tigo Energy Global Quality Program Marks 1,500 Green Glove Installer Engagements18.2.2026 12:00:00 CET | Press release
Continuous quality improvement produces better outcomes for solar customers with Green Glove installer support, and business process updates internally and in the field. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company’s vast network of solar installers has logged 1,500 Green Glove service program engagements. The Green Glove program helps reinforce the Company’s ongoing commitment to Total Quality Solar and deliver the best possible installer experience for participants, such as Brighthouse Solar of Central California. In addition to the Green Glove program, Tigo has deployed more than 12,000 customized onboarding sequences, across ten countries, to bring new installation companies up to speed on all things Tigo. From region-specific information to product and software training tips, these sequences are designed to ensure that installers have what they need based on their com
Battery Ventures Raises $3.25 Billion to Back Innovative Tech Companies Worldwide18.2.2026 10:00:00 CET | Press release
Battery—continuing to invest across the venture capital and buyout markets—has a single close on an oversubscribed fund Battery Ventures, the global, technology-focused investment firm, has closed a new, $3.25 billion fund to continue backing technology companies globally with a focus on the U.S., Europe and Israel. The new fund, Battery Ventures XV, comes on the heels of 15 announced exit events for the firm in 2025. Over the last five years Battery funds have realized more than $10 billion in liquidity, a testament to the firm’s stage-diversified approach. “We’re excited to build on our past success and partner with new, innovative companies in this dynamic market—driven, in large part, by the rise of artificial intelligence,” said Michael Brown, a Battery general partner. “To us, AI is ushering in one of the most consequential eras in the history of technology. We understand the gravity of this moment and feel well-suited to capitalize on the opportunity, given our global reach and
NICT Showcases Beyond 5G/6G Technologies at MWC Barcelona 202618.2.2026 09:00:00 CET | Press release
Japan's only national ICT research institute to present live demonstrations of terahertz-band wireless transmission, AI-driven communications, and advanced security technologies at Hall 6, Stand F54 National Institute of Information and Communications Technology (NICT), Japan’s leading public research organization in information and communications technology, today announced that it will exhibit at Mobile World Congress (MWC) Barcelona 2026, taking place from March 2–5, 2026, at Hall 6, Stand F54. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216620427/en/ NICT BOOTH NICT’s presence highlights Japan’s leadership in Beyond 5G and 6G research and development activities, addressing the growing limitations of current mobile networks as data traffic and connected devices continue to increase across Europe and globally. While 5G deployment is expanding, emerging applications such as AI-driven services, real-time analytics, and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
